

Sep 30, 2019 Version 2

## Echocardiography: Mouse V.2

DOI

[dx.doi.org/10.17504/protocols.io.7s7hnhn](https://dx.doi.org/10.17504/protocols.io.7s7hnhn)



E. Dale Abel<sup>1</sup>

<sup>1</sup>University of Iowa

Diabetic Complications Consortium  
Tech. support email: [rmcindoe@augusta.edu](mailto:rmcindoe@augusta.edu)



Lili Liang

OPEN  ACCESS



DOI: [dx.doi.org/10.17504/protocols.io.7s7hnhn](https://dx.doi.org/10.17504/protocols.io.7s7hnhn)

External link: <https://www.diacomp.org/shared/document.aspx?id=39&docType=Protocol>

**Protocol Citation:** E. Dale Abel 2019. Echocardiography: Mouse. **protocols.io**  
<https://dx.doi.org/10.17504/protocols.io.7s7hnhn>

**License:** This is an open access protocol distributed under the terms of the **Creative Commons Attribution License**, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

**Protocol status:** Working

**We use this protocol and it's working**

**Created:** September 30, 2019

**Last Modified:** September 30, 2019

**Protocol Integer ID:** 28223

**Keywords:** transthoracic echocardiography, Cardiovascular

## Abstract

### Summary:

This protocol describes the procedure used by the DiaComp for transthoracic echocardiography in awake mice.


### Diabetic Complication:



Cardiovascular

## Materials

### MATERIALS

 Isoflurane (1%)

- 1 We perform transthoracic echocardiography in awake mice. If anesthesia is required we currently favor the use of inhaled isoflurane (1%), delivered via nose cone. The anesthesia flow can be titrated to minimize any reduction in heart rate. If inhaled anesthesia is not available, we have also had success with avertin (tribromoethanol)(0.2 ml/10 g body weight) or chloral hydrate (0.5 mg/g body weight). Heart rates are generally maintained at more than 400 per minute with these regimens. The chest hair is removed with a topical depilatory agent. Limb leads were attached for electrocardiogram gating, and the animals are imaged in the left lateral decubitus position with a 13-MHz linear probe (Vivid FiVe; GE Medical Systems, Milwaukee, Wisconsin, USA).

Two-dimensional images are recorded in parasternal long- and short-axis projections with guided M-mode recordings at the midventricular level in both views. Left ventricular (LV) cavity size and wall thickness are measured in at least three beats from each projection and averaged. LV wall thickness [interventricular septum (IVS) and posterior wall (PW) thickness] and internal dimensions at diastole and systole (LVIDd and LVIDs, respectively) are measured. LV fractional shortening  $[(LVIDd - LVIDs)/LVIDd]$ , relative wall thickness  $[(IVS \text{ thickness} + PW \text{ thickness})/LVIDd]$ , and LV mass  $[1.05 (IVS \text{ thickness} + LVIDd + PW \text{ thickness})^3 - LVIDd^3]$  are calculated from the M-mode measurements.